What is AMO Pharma?
AMO Pharma is a biopharmaceutical company dedicated to identifying and advancing novel therapies for severe and debilitating diseases, with a particular focus on rare and severe childhood-onset neurogenetic disorders. The company targets patient populations with substantial unmet medical needs, aiming to develop treatments where options are currently limited or nonexistent. This strategic focus positions AMO Pharma within a critical niche of the pharmaceutical market, emphasizing innovation in rare disease therapeutics.
How much funding has AMO Pharma raised?
AMO Pharma has raised a total of $60M across 2 funding rounds:
Private Equity
$25M
Unspecified
$35M
Private Equity (2015): $25M, investors not publicly disclosed
Unspecified (2020): $35M led by Undisclosed
Key Investors in AMO Pharma
Undisclosed Investors
Undisclosed Investors
What's next for AMO Pharma?
With a history of substantial investment, including a major enterprise-level funding round, AMO Pharma is poised for continued development and expansion. The company's commitment to addressing rare and severe childhood-onset neurogenetic disorders suggests a long-term strategy focused on clinical trials, regulatory approvals, and eventual market entry for its therapeutic candidates. Future growth will likely involve further strategic partnerships, potential follow-on financing rounds to support late-stage development, and the scaling of its research and development operations to bring promising treatments to patients.
See full AMO Pharma company page
